Laplace Interventional Raises $22M to Support Tricuspid Valve Trials

Laplace Interventional, a Minnesota-based medical device company, has raised $22 million in a Series C funding round to accelerate the development of its transcatheter tricuspid valve replacement system. The round was led by a global strategic investor, with new contributions from Aphelion Cardeation and Unorthodox Ventures, and continued support from existing backers Engage Venture Partners, JWC Venture, and Features Capital.

The funding is set to support the completion of the company's ongoing Early Feasibility Study (EFS) in the United States and abroad, while also helping to prepare for a pivotal clinical trial. As part of this investment round, Ned Scheetz, Founding Managing Partner at Aphelion Capital, has joined Laplace Interventional’s Board of Directors.

Early clinical experiences and patient outcomes

Laplace Interventional is developing a minimally invasive solution for patients with Tricuspid Regurgitation (TR), a condition often requiring complex surgery. The company’s approach allows for valve replacement without the need for open-heart surgery, aiming to reduce post-procedure complications. Early clinical experience in the US EFS showed promising patient outcomes.

According to Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center in Portland, Oregon, three patients were treated with the Laplace system, and all were discharged within one to two days. Dr. Jones said this was their first time using a dedicated tricuspid valve platform, noting the intuitive deployment and flexibility of the device in challenging anatomical cases.

So far, the company has enrolled 22 patients in the US and a total of 25 globally in its early feasibility studies. These initial findings will help guide the development of future clinical phases.

Management comments and strategic direction

Ramji Iyer, PhD, Founder and CEO of Laplace Interventional, emphasized the importance of the new funding milestone, stating that it validates the company’s development efforts. Iyer expressed appreciation for the trust shown by patients, clinicians, and investors, and shared that the team is focused on advancing toward pivotal trial readiness.

In a statement, Ned Scheetz of Aphelion Capital said, “We are inspired by Laplace’s innovative solution for TR and its potential to transform care for millions of patients worldwide.” He noted that Aphelion Cardeation, a venture fund aligned with the mission of the American Heart Association, is pleased to back the company’s mission.

Device not yet approved for commercial use

Laplace Interventional clarified that the device remains in development and has not received approval or clearance from the FDA or any other global regulatory authority. The company will continue working through clinical validation steps before entering commercial phases.